Neurocognitive Disorders News | Major & Mild Neurocognitive Disorder Research

Choroid Plexus Volume Associated With Advanced Cognitive Impairment

Among patients with cognitive symptoms, choroid plexus volume is associated with the stage of cognitive impairment.

Cognitive Impairment 3 to 12 Months After COVID-19 Hospitalization

Researchers assessed the frequency and severity of cognitive impairments over time and specifically 1 year after hospitalization in patients who contracted COVID-19.

Is Late-Onset Depression a Prodrome to Major Neurocognitive Disorder?

In a case-control study, researchers assessed the potential link between late-onset depression and the risk of developing major cognitive disorder.

Memory Concerns Stable, but Incidence of Cognitive Decline Increased

Rates of memory concerns among older adults remained stable, but the incidence of cognitive decline more than doubled between 2009 and 2018.

Risk for Decline Up for Low-Income Seniors After ICU Stay

Community-dwelling older adults with dual eligibility for Medicare and Medicaid have an increased risk for decline in function and cognition after intensive care unit (ICU) hospitalization.

In the transition from RRMS to SPMS, inflammation that occurs early in the disease process slowly decreases over time, but a gradual worsening of symptoms occurs. The challenge for clinicians is to determine whether worsening symptoms are from the last relapse, or whether the patient has progressed to SPMS. A careful history of changes in a patient’s symptoms, neurologic examination, and MRI can help determine whether the transition has occurred. Interferon beta (Avonex, Betaseron, Extavia and Rebif), Aubagio (teriflunomide), Gilenya (fingolimod), Tecfidera (dimethyl fumarate), and Tysabri (natalizumab) are approved by the FDA for use in relapsing forms of MS, including SPMS. Many of those who progress to SPMS continue using these medications unless they are no longer adequately controlling disease activity. In this case, patients may transition to Novantrone (mitoxantrone), the only medication approved by the FDA specifically for SPMS, as well as worsening relapsing MS.

The Link, Potential Mechanism Between Sarcopenia and Motoric Cognitive Risk Syndrome

Using an established moderated mediation model, researchers investigated the association and potential pathways between sarcopenia and motoric cognitive risk syndrome in older adults.